Stock 002940 ZHEJIANG ANGLIKANG PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zhejiang AngLiKang Pharmaceutical CO.,LTD.

Equities

002940

CNE100003GC2

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
16.58 CNY +3.82% Intraday chart for Zhejiang AngLiKang Pharmaceutical CO.,LTD. +11.20% -23.63%
Apr. 02 Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023. CI
Feb. 06 Anglikang Pharmaceutical Signs Licensing Deal for Affinity Biomedical's Tumor Drug MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022
Capitalization 1 3,219 2,693 3,968 3,486 3,684
Enterprise Value (EV) 1 2,618 2,067 3,126 2,739 3,226
P/E ratio 23.4 x 23.9 x 22.9 x 28.6 x 29.1 x
Yield 2.1% 3.34% 1.21% 0.83% 1.11%
Capitalization / Revenue 2.57 x 1.93 x 3.08 x 2.53 x 2.35 x
EV / Revenue 2.09 x 1.48 x 2.42 x 1.98 x 2.06 x
EV / EBITDA 15.9 x 11.8 x 15.4 x 13.9 x 16.6 x
EV / FCF 44.8 x 46.3 x 72.5 x 106 x 61.7 x
FCF Yield 2.23% 2.16% 1.38% 0.95% 1.62%
Price to Book 3.5 x 2.79 x 3.01 x 2.55 x 2.45 x
Nbr of stocks (in thousands) 189,225 189,225 201,728 201,728 197,397
Reference price 2 17.01 14.23 19.67 17.28 18.66
Announcement Date 3/29/19 4/2/20 4/16/21 4/15/22 3/31/23
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 873.2 1,255 1,396 1,290 1,380 1,568
EBITDA 1 160.3 164.8 175.6 202.9 197.2 193.9
EBIT 1 127.1 126.2 138.1 162 151 133
Operating Margin 14.56% 10.06% 9.89% 12.56% 10.94% 8.48%
Earnings before Tax (EBT) 1 123.5 137.3 153.7 210.7 172.6 146.9
Net income 1 87.4 108.7 112.3 163.7 119.8 127.3
Net margin 10.01% 8.66% 8.04% 12.69% 8.68% 8.12%
EPS 2 0.6136 0.7277 0.5945 0.8609 0.6040 0.6414
Free Cash Flow 1 118 58.39 44.65 43.11 25.92 52.3
FCF margin 13.51% 4.65% 3.2% 3.34% 1.88% 3.33%
FCF Conversion (EBITDA) 73.57% 35.44% 25.43% 21.25% 13.15% 26.97%
FCF Conversion (Net income) 134.98% 53.72% 39.77% 26.33% 21.63% 41.08%
Dividend per Share - 0.3567 0.4756 0.2378 0.1427 0.2069
Announcement Date 4/13/18 3/29/19 4/2/20 4/16/21 4/15/22 3/31/23
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 57.7 602 626 842 747 458
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 118 58.4 44.6 43.1 25.9 52.3
ROE (net income / shareholders' equity) 29.2% 17.8% 12.7% 15.1% 9.91% 8.46%
ROA (Net income/ Total Assets) 9.72% 6.64% 6.05% 6.09% 4.69% 3.55%
Assets 1 899.1 1,638 1,857 2,690 2,556 3,584
Book Value Per Share 2 2.510 4.860 5.100 6.540 6.780 7.610
Cash Flow per Share 2 0.9800 3.270 2.790 4.230 3.490 3.730
Capex 1 54.8 68.2 75.6 91 87.3 68.8
Capex / Sales 6.27% 5.43% 5.41% 7.05% 6.33% 4.39%
Announcement Date 4/13/18 3/29/19 4/2/20 4/16/21 4/15/22 3/31/23
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
ZHEJIANG ANGLIKANG PHARMACEUTICAL CO.,LTD. Stock Zhejiang AngLiKang Pharmaceutical CO.,LTD.
-23.63% 435M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 332B
ABBVIE INC. Stock AbbVie Inc.
+4.23% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
NOVARTIS AG Stock Novartis AG
+4.71% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
AMGEN INC. Stock Amgen Inc.
-4.04% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002940 Stock
  4. Financials Zhejiang AngLiKang Pharmaceutical CO.,LTD.